KCM
VINC

Kingdon Capital Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Kingdon Capital Management’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,250
Closed -$1.95M – 112
2024
Q1 		$1.95M Hold
19,250
– – 0.21% 80
2023
Q4 		$454K Hold
19,250
– – 0.06% 74
2023
Q3 		$389K Hold
19,250
– – 0.04% 72
2023
Q2 		$501K Hold
19,250
– – 0.05% 79
2023
Q1 		$400K Hold
19,250
– – 0.08% 56
2022
Q4 		$393K Hold
19,250
– – 0.08% 47
2022
Q3 		$531K Hold
19,250
– – 0.07% 55
2022
Q2 		$508K Hold
19,250
– – 0.09% 66
2022
Q1 		$1.54M Hold
19,250
– – 0.16% 74
2021
Q4 		$3.92M Buy
19,250
+4,005
+26% +$999K 0.45% 55
2021
Q3 		$4.93M Buy
15,245
+5,074
+50% +$1.48M 0.6% 40
2021
Q2 		$2.64M Buy
+10,171
New +$3.1M 0.31% 57

Other funds holding VINC

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kingdon Capital Management's VINC Position: Q2 2024 in Review

Kingdon Capital Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2024, closing a stake of 19,250 shares — an estimated $1.95M sold.

Kingdon Capital Management first reported a position in VINC in Q2 2021 and held it in 12 quarters. The position peaked at $4.93M in Q3 2021. 27 funds tracked by Wall St. Rank hold VINC as of Q2 2024.

  • Kingdon Capital Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Kingdon Capital Management sold 19,250 Vincerx Pharma, Inc. Common Stock shares in Q2 2024, an estimated $1.95M.
  • Kingdon Capital Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • Kingdon Capital Management's Vincerx Pharma, Inc. Common Stock position peaked at $4.93M in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2024.

Based on Kingdon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.